About Canopy Growth Corporation - Common Shares (CGC)
Canopy Growth Corp is a leading player in the cannabis industry, focusing on the production and distribution of a wide range of cannabis products. The company is engaged in cultivating and processing cannabis for both medical and recreational purposes, offering various forms such as dried flower, oils, edibles, and beverages. With a commitment to innovation, Canopy Growth invests in research and development to create high-quality products that meet consumer demands and adhere to evolving regulations. The company also emphasizes sustainability and responsible business practices, aiming to shape the future of cannabis consumption and enhance the overall experience for consumers. Read More
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. (“MTL”), a wholly-owned subsidiary of the Company. The dual milestone represents the Company’s first international product release following its recent acquisition of MTL.
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) expects to release its financial results for the quarter and fiscal year ended March 31, 2026 before financial markets open on June 15, 2026. The Company also announced it plans to file restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024 and to certain of the interim periods therein (the “Refiling”), in conjunction with its filing of financial results for the year ended March 31, 2026 on June 15, 2026, as further described below and in the Company’s material change report and the Company’s Current Report on Form 8-K each dated May 15, 2026.
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and Spectrum Therapeutics today announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio.
A directive signed by Acting AG Todd Blanche on April 22 and put into force the next day shifts two categories of cannabis from Schedule I of the CSA to Schedule III. One includes marijuana-based medications approved by the FDA. The other applies to cannabis produced, distributed, or sold under state-issued medical licenses.
A directive signed by Acting AG Todd Blanche on April 22 and put into force the next day shifts two categories of cannabis from Schedule I of the CSA to Schedule III. One includes marijuana-based medications approved by the FDA. The other applies to cannabis produced, distributed, or sold under state-issued medical licenses.
Canopy Growth Corporation (“Canopy Growth”, “Canopy” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced a refresh of Tweed, one of Canada’s most recognizable cannabis brands, alongside a national summer campaign, “There’s a Tweed for That.”
Low-dose THC drinks may be gaining shelf space in bars and retail chains, but they are not resonating with marijuana shoppers in California, according to industry representatives .
Low-dose THC drinks may be gaining shelf space in bars and retail chains, but they are not resonating with marijuana shoppers in California, according to industry representatives .
